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The purpose of the study was to evaluate the efficacy and safety of docetaxel plus epirubicin (ET) and of 5-fluorouracil plus epirubicin
and cyclophosphamide (FEC) as first-line chemotherapy for metastatic breast cancer. A total of 142 patients (intent-to-treat (ITT))
with at least one measurable lesion were randomised to receive docetaxel 75mgm
 2 plus epirubicin 75mgm
 2 or 5-fluorouracil
500mgm
 2 plus epirubicin 75mgm
 2 and cyclophosphamide 500mgm
 2 intravenously once every 3 weeks for up to eight cycles.
Prophylactic granulocyte-colony-stimulating factor was only permitted after the first cycle, if required. Per-protocol analysis (n¼132)
gave an overall response rate for ET of 63.1% (95% confidence interval (CI), 50–78%) and for FEC 34.3% (95% CI, 23–47%) after a
median seven and six cycles, respectively. Intent-to-treat population (n¼142) gave an overall response rate for ET of 59% (95% CI,
47–70%) and for FEC 32% (95% CI, 21–43%) after a median seven and six cycles, respectively. The median response duration for ET
was 8.6 months (95% CI, 7.2–9.6 months) and for FEC 7.8 months (95% CI, 6.5–10.4 months). The median time to progression
(ITT) for ET was 7.8 months (95% CI, 5.8–9.6 months) and for FEC 5.9 months (95% CI, 4.6–7.8 months). After a median follow-up
of 23.8 months, median survival (ITT) for ET and FEC were 34 and 28 months, respectively. Nonhaematologic grade 3–4 toxicities
were infrequent in both arms. Haematologic toxicity was more common with ET and febrile neutropenia was reported in 13 patients
(18.6%) in the ET group. Two deaths in the ET group were possibly related to study treatment. In conclusion, both ET and FEC were
associated with acceptable toxicity. ET is a highly active first-line therapy for metastatic breast cancer.
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Only a small number of patients with metastatic breast cancer
achieve long-term survival (complete remission for more than 5
years in 3.1% of patients in one survey) (Greenberg et al, 1996).
The median survival of women with hormone-insensitive ad-
vanced breast cancer remains at around 2 years, and the chief aims
of management continue to be prolonging survival and easing of
symptoms, minimising treatment toxicity, and optimising of
quality of life (Perez, 1999).
Treatment of metastatic breast cancer usually involves hormone
therapy and/or chemotherapy with or without a biologic agent (eg
trastuzumab in patients with tumours overexpressing HER2).
Radiation therapy and/or surgery may be indicated for patients
with limited, but symptomatic metastases. Cytotoxic chemother-
apy is usually recommended for patients whose tumours have
progressed on hormonal therapy, those with hormone receptor-
negative tumours, and those with visceral metastases (National
Cancer Institute, 2002).
The experience of two decades of clinical studies has shown that,
in general, the use of combination chemotherapy is associated with
higher response rates than single-agent treatment in metastatic
breast cancer (Fossati et al, 1998). As recently reviewed (Crown
et al, 2002; Nabholtz et al, 2002), the anthracyclines are well
established in first-line chemotherapy for metastatic breast cancer,
and anthracycline-containing regimens have been shown to confer
higher response rates and longer survival overall than nonan-
thracycline combinations such as cyclophosphamide plus metho-
trexate and 5-FU (CMF) (A’Hern et al, 1993). First-line
combinations include doxorubicin plus cyclophosphamide (AC),
epirubicin plus cyclophosphamide (EC), 5-fluorouracil (5-FU) plus
doxorubicin and cyclophosphamide (FAC), or 5-FU plus epirubi-
cin and cyclophosphamide (FEC).
Of the novel chemotherapeutic agents introduced during the
1990s, the taxanes have emerged as some of the most active drugs
in breast cancer. The semisynthetic taxoid docetaxel (Taxotere
s)
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lhas been shown in phase III studies to be effective in metastatic
disease previously treated with an anthracycline or alkylating agent
(Chan et al, 1999; Nabholtz et al, 1999; Sjo ¨stro ¨m et al, 1999;
Bonneterre et al, 2002). Docetaxel has shown substantial activity
when combined with an anthracycline, with two notable phase III
trials showing significantly higher tumour response rates with
docetaxel plus doxorubicin than with AC, and with docetaxel plus
doxorubicin and cyclophosphamide (TAC) than with FAC
(Nabholtz et al, 2001, 2003).
Epirubicin is an anthracycline that may be less cardiotoxic than
doxorubicin, and noncomparative phase II studies have shown
very encouraging responses to treatment when this drug is
combined with docetaxel as first-line therapy in metastatic breast
cancer (French Epirubicin Study Group, 1998; Airoldi et al, 2001;
Morales et al, 2002; Pharmacia Corporation, 2002; Yeo et al, 2002).
The present randomised phase II study evaluated epirubicin
75mgm
 2 plus docetaxel 75mgm
 2 (ET) and the standard FEC
triple combination, using the same dose of epirubicin (75mgm
 2).
MATERIALS AND METHODS
This prospective, randomised, open label study was carried out
across 12 centres in France. The study protocol was approved by
the ethics committee at each participating centre.
Patients
Women aged 18 to 65 years were required to have histologically or
cytologically proven breast cancer with metastases and at least one
bidimensionally measurable lesion. Written informed consent was
required from each patient before enrolment. Prior adjuvant or
neoadjuvant therapy, with or without anthracyclines (maximum
cumulative dose of p310mgm
 2 for doxorubicin, 460mgm
 2 for
epirubicin and 75mgm
 2 for mitoxanthrone), was allowed if
completed at least 12 months before the study, as were adjuvant
locoregional radiotherapy or hormone therapy if completed at
least 4 weeks or immediately before study entry, respectively.
Other requirements were a World Health Organization (WHO)
performance status of p2, left ventricular ejection fraction (LVEF)
within the normal range for each institution, no symptomatic
central nervous system metastases, and adequate haematologic,
renal and liver function. Prior treatment with a taxane and
previous chemotherapy for metastatic breast cancer was not
allowed.
Patients were not eligible if they had localised or inoperable
locally advanced disease, history of any other cancer (with the
exception of nonmelanoma skin cancer or cervical carcinoma in
situ), other significant medical conditions (most notably cardiac,
neurologic, or psychiatric disorders), any uncontrolled infection,
or sensory or motor neuropathy of severity greater than WHO
grade 1. Patients receiving a corticosteroid at a dosage equivalent
to 20mgday
 1 or more of methylprednisolone, those in whom
corticosteroid treatment was contraindicated, and pregnant or
breast-feeding women were excluded. Effective contraception was
required for women of child-bearing age.
Treatment plan
Patients were assigned according to a centralised predefined
schedule with randomisation stratified according to centre to one
of two treatment arms: epirubicin (Ellence
s, Farmorubicin
s)
75mgm
 2 over 10min plus docetaxel (Taxotere
s; Aventis,
Antony, France) 75mgm
 2 over 1h (ET), or 5-FU 500mgm
 2
over 1h plus epirubicin 75mgm
 2 over 10min plus cyclopho-
sphamide 500mgm
 2 over 30min (FEC). All agents were given by
intravenous infusion once every 21 days for up to eight cycles, with
a maximum allowable cumulative dose of anthracycline equivalent
to doxorubicin 550mgm
 2. Prophylactic premedication with
corticosteroids (six doses of methylprednisolone 40mg or
equivalent) was given for 3 days to all patients on the ET arm.
Prophylactic antiemetic treatment was mandatory for all patients,
with the addition of loperamide for moderate to severe diarrhoea if
necessary.
Assessment of response and toxicity
The pretreatment evaluation included a full medical history and
physical examination, haematology and biochemistry, and visceral
tumour assessment. The radiologic examination included front
and lateral chest X-rays, abdominal ultrasound and/or computed
tomography (CT) scan, systematic bone scan, and standard X-rays,
CT scans, or magnetic resonance imaging of suspicious lesions. An
electrocardiogram and echocardiography were performed in all
patients at baseline and particularly in case of history of cardiac
disease or prior cumulative dose of anthracycline or anthracene-
dione above the specified limits.
Physical examinations and liver function tests were repeated at
the beginning of each treatment cycle. Assessments of left
ventricular function with multiple gated acquisition scanning or
echocardiography were performed every four cycles until the
maximum cumulative dose of anthracycline was reached, and
every two cycles thereafter. Haematologic analysis was carried out
immediately before each treatment and on day 7 (with an
additional test on day 14 in case of fever). Prophylactic
granulocyte-colony-stimulating factor (G-CSF) was given if the
absolute neutrophil count (ANC) decreased to o0.5 10
9l
 1 for
more than 7 days and/or the platelet count was reduced to
p25 10
9l
 1 and/or febrile neutropenia was apparent (grade 4
neutropenia with concomitant temperature X38.51C, which
required intravenous antibiotics or hospitalisation). If a second
neutropenic episode occurred despite G-CSF, the dose of docetaxel
in the ET group was to be reduced to 60mgm
 2 for all remaining
cycles, with no further reductions allowed. In the event of a second
episode in the FEC group, the dose of epirubicin was reduced to
60mgm
 2 until recovery to ANC X1.5 10
9l
 1. Treatment
withdrawal was required for a third episode. Dose delay to a
maximum of 2 weeks was allowed for patients with ANC
o1.5 10
9l
 1 and/or platelet count o100 10
9l
 1 at day 22
(second cycle).
A 2-week dose delay was allowed for patients with grade 3
hyperbilirubinaemia, but treatment withdrawal was required for
grade 4 hyperbilirubinaemia. Dose delay was also allowed for
patients with abnormal hepatic enzyme levels. Patients were
withdrawn from the study if anaphylaxis or a recurrent severe
(National Cancer Institute Common Toxicity Criteria (NCI-CTC
version 2.0) grade 4 hypersensitivity reaction was observed. Oral
treatment with spironolactone 50mgday
 1 was permitted for fluid
retention, with the addition of furosemide if necessary. Cessation
of chemotherapy was required in patients showing signs of
congestive heart failure, functional criteria for cardiotoxicity, or
decrease of more than 10% from baseline in LVEF to below the
lower limit of normal for the institution.
Target lesions were assessed every two cycles. All objective
responses were confirmed at least 4 weeks after the initial response
determination and reviewed by an independent committee of
radiologists. A complete tumour assessment was carried out 28
days after the last infusion, with monthly follow-up thereafter for 6
months, then every 2 months for 1 year. Tumour responses in
measurable and/or assessable lesions were assessed according to
WHO criteria (World Health Organization, 1979). The best overall
response was taken as the best response obtained from the start of
treatment until disease progression. The duration of response was
the time from complete (CR) or partial (PR) response to the time
that recurrent or progressive disease or death was first noted.
Survival was defined as the time from beginning treatment to the
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ltime of death from any cause or the date of last contact if death was
not recorded before the cutoff date.
Adverse events were monitored from the start of chemotherapy
to 30 days after the last infusion and were graded using the NCI-
CTC criteria. Serious adverse events were those that resulted in
death or were life threatening, required or prolonged hospitalisa-
tion, caused persistent or significant disability or incapacity, or
were considered important medical events.
Statistical methods
The primary objective of the study was to evaluate the efficacy of
EC and FEC in terms of objective tumour response rate (ORR).
Secondary end points included time to progression (TTP),
duration of response, survival, and tolerability. Response rates
were analysed for the intent-to-treat (ITT) population, which was
defined as patients who had received at least one cycle of treatment
and for the per-protocol population, which was defined as patients
assessable for response who had received at least two cycles of
chemotherapy. Time to progression and overall survival were
calculated for the ITT population, which consisted of all patients
who had received at least one cycle of study treatment.
Statistical analyses were carried out using SAS software Version
6.08. The TTP, response duration, and survival data were subjected
to Kaplan–Meier analysis with censoring. The sample size as
planned by protocol was based on an estimated ORR of 65% at the
end of the eighth cycle. The number of assessable patients required
per group to confer 95% power was calculated to be 88, and it was
therefore planned to enroll 100 patients per arm.
RESULTS
Patients
A total of 142 patients were enrolled and randomised between
September 1998 and November 2000, 70 to ET and 72 to FEC. The
planned population was not included due to difficulties about
enrolment. The respective assessable populations were 65 and 67.
In the ET arm, one patient withdrew consent, there were three
early deaths (one each due to sepsis, gastrointestinal haemorrhage,
and a cause unrelated to treatment), and one patient had no
assessable lesion. In the FEC arm, one patient withdrew consent
and four patients had no assessable lesions. Patient and tumour
characteristics were generally similar at baseline between groups,
although the proportion of patients with an original diagnosis of
stage IV disease was higher in the ET than in the FEC arm (33 vs
21%). In addition, more patients in the ET group showed
metastatic involvement of the lung, liver, skin, bone, or more
than three organs overall. The median age was 54 years, and 97%
of patients had a WHO performance status of 0 to 1. Overall 49% of
patients received previous adjuvant or neoadjuvant chemotherapy,
42% with an anthracycline-based regimen. A slightly higher
proportion of patients in the FEC group had oestrogen or
progesterone receptor-positive tumours (Table 1).
Treatment administration
A total of 441 and 430 cycles of treatment were administered in the
ET and FEC arms, respectively, with median cycle numbers per
patient of 7 for ET and 6 for FEC (range, 1–9 for both ET and
FEC). The median overall relative dose intensity was 1, and
treatment was delayed by more than 7 days in 3% of cycles in both
groups. Epirubicin dose reduction was required in 4.5% of ET and
0.7% of FEC cycles. Treatment was discontinued due to completion
of therapy in 75 patients (42 ET and 33 FEC) and due to disease
progression in 40 patients (14 ET and 26 FEC).
Poststudy treatments for ET and FEC arms, respectively, were as
follows: surgery in 4.2 and 5.5% of patients, radiotherapy in 21.4
and 22.2%, hormonal therapy in 58.6 and 61.1%, and chemother-
apy in 67.1% and 79.1. Second-line (during poststudy period)
docetaxel was administered to 56.9% of FEC-treated patients and
8.6% of ET-treated patients.
Response and survival
According to the per-protocol analysis, 65 patients in the ET group
and 67 in the FEC group were evaluable for response (Table 2). The
ORR in each group was 63.1% (95% confidence interval (CI), 50–
78%) with ET and 34.3% (95% CI, 23–47%) with FEC. According
to the ITT population, the ORR was 59% (95% CI, 47–70%) with
ET and 32% (95% CI, 21–43%) with FEC. CRs were reported in
Table 1 Patient and disease characteristics at baseline
No. of patients (%)
ET (n¼70) FEC (n¼72)
Age (years)
Median 54 54
Range 34–73 23–71
WHO performance status
0 43 (61) 52 (72)
1 25 (36) 17 (24)
2 2 (3) 3 (4)
More than three organs involved 45 (64) 32 (44)
Type of lesion
Lymph node superficial 24 (34) 17 (24)
Lymph node deep 20 (29) 24 (33)
Breast 25 (36) 19 (26)
Lung 36 (54) 27 (38)
Liver 45 (64) 41 (57)
Skin 13 (19) 6 (8)
Bone 41 (59) 35 (49)
Other 9 (13) 2 (3)
Stage at initial diagnosis
I 7 (10) 14 (19)
II 30 (43) 32 (44)
III 6 (9) 8 (11)
IV 23 (33) 15 (21)
Unknown 4 (6) 3 (4)
SBR tumour grade
a
1 5 (7) 6 (8)
2 42 (60) 32 (44)
3 17 (24) 24 (33)
Unknown 6 (9) 10 (14)
Hormone receptor status
ER positive 38 (54) 48 (67)
ER negative 26 (37) 20 (28)
PR positifs 36 (51) 43 (60)
PR negative 28 (40) 25 (35)
Unknown 6 (9) 4 (6)
Prior chemotherapy
None 37 (53) 35 (49)
Anthracycline based 29 (41) 31 (43)
Nonanthracycline based 4 (6) 6 (8)
ER¼estrogen receptor; ET¼epirubicin plus docetaxel; FEC¼5-fluorouracil plus
epirubicin plus cyclophosphamide; PR¼progesterone receptor; SBR¼Scarff–
Bloom–Richardson; WHO¼World Health Organization.
aScarff–Bloom–Richard-
son system: grade tumour on the basis of glandular formation, mitotic rate, and
nuclear pleiomorphism. Grade 1¼well differentiated; grade 2¼moderately
differentiated; grade 3¼poorly differentiated.
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ltwo patients receiving ET and one patient on FEC (Table 2). The
median duration of response was 8.6 months (95% CI, 7.2–9.6
months) for ET and 7.8 months (95% CI, 6.5–10.4 months) for
FEC at the cutoff date. The median TTP for the ITT population was
7.8 months (95% CI, 5.8–9.6 months) in the ET group and 5.9
months (95% CI, 4.6–7.8 months) in the FEC group (Figure 1).
After a median follow-up of 23.8 months, median survival in the
ITT population was 34 months in the ET group and 28 months in
the FEC group; 37 (53%) and 31 (43%) patients, respectively, were
still alive at the cutoff date (Figure 2).
Toxicity
The main NCI-CTC grade 3 to 4 toxicities were haematologic and
are summarised in Table 3. Febrile neutropenia occurred in 13
patients (18.6%) in the ET group, and of the four patients who
received G-CSF after the first neutropenic episode, only one
experienced a second episode. Two patients in the FEC group
received prophylactic G-CSF. Per-patient incidences of neutrope-
nia were similar between groups, although this adverse event was
seen during more cycles of ET than FEC (Table 3).
Nonhaematologic adverse events possibly or probably linked to
study treatment were infrequent in both groups (Table 4). Grade
3–4 alopecia, asthenia, nausea, and vomiting affected more than
5% of patients in either group. Serious adverse events considered
by the investigators to be possibly or probably related to study
treatment were more frequent in the ET group than with FEC (33
vs 3%). The majority of these events were accounted for by
episodes of febrile neutropenia; others included asthenia, periph-
eral neuropathy, jugular vein thrombosis, skin infection, and
decreased LVEF. Seven patients withdrew due to toxicity (five in
the ET and two in the FEC group). As reported above, there were
three early deaths in the ET group. Two of these deaths were
potentially related to study treatment (one attributed to sepsis and
one attributed to gastrointestinal haemorrhage occurring within 9
and 11 days after the last infusion, respectively). The third death
was not related to study treatment, was of unexplained cause, and
occurred within 9 days after the last infusion.
Overall, the proportion of patients who experienced reductions
of at least 10 or 20% in LVEF was consistently higher with FEC
than with ET, but grade 3–4 cardiac disorders occurred in two
patients in the ET arm and not in the FEC arm.
DISCUSSION
The present study shows that ET (epirubicin 75mgm
 2 plus
docetaxel 75mgm
 2 every 3 weeks) is a highly active first-line
treatment for metastatic breast cancer. Although comparison of
the two arms was not prospectively planned, the results favour ET,
Table 2 Clinical responses to chemotherapy (per-protocol analysis)
No. of patients (%)
ET (n¼65) FEC (n¼67)
CR 2 (3.1) 1 (1.5)
PR 39 (60.0) 22 (32.8)
Stable disease 20 (30.8) 36 (53.7)
Progressive disease 4 (6.2) 8 (11.9)
ORR
a 41 (63.1, 95% CI, 50–78) 23 (34.3, 95% CI, 23–47)
CR¼complete response; PR¼partial response; ORR¼objective response rate;
CI¼confidence interval; ET¼epirubicin plus docetaxel; FEC¼5-fluorouracil plus
epirubicin plus cyclophosphamide.
aORR¼CR+PR.
100
90
80
70
60
50
40
30
20
10
4 2 06 8 1 0 1 2 1 4
P
r
o
b
a
b
i
l
i
t
y
 
(
%
)
Time (months)
Arm A (ET)
Arm B (FEC)
Figure 1 Time to tumour progression (ITT analysis).
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Figure 2 Overall survival (ITT analysis).
Table 3 Grade 3 and 4 haematologic toxicity
No. of patients (%) No. of cycles (%)
ET (n¼70) FEC (n¼72) ET (n¼441) FEC (n¼430)
Neutropenia 47 (67.1) 43 (59.7) 133 (30.2) 95 (22.1)
Febrile neutropenia 13 (18.6) 0 21 (4.8) 0
Leukopenia 31 (44.3) 24 (33.3) 101 (22.9) 47 (10.9)
Anaemia 3 (4.3) 1 (1.4) 3 (0.7) 1 (0.2)
Thrombocytopenia 2 (2.9) 1 (1.4) 2 (0.5) 1 (0.2)
ET¼epirubicin plus docetaxel; FEC¼5-fluorouracil plus epirubicin plus cyclo-
phosphamide.
Table 4 Grade 3 and 4 nonhaematologic toxicity
No. of patients (%) No. of cycles (%)
ET (n¼70) FEC (n¼72) ET (n¼441) FEC (n¼430)
Alopecia 38 (54.3) 24 (33.3) 47 (10.7) 30 (7.0)
Asthenia 7 (10.0) 4 (5.6) 10 (2.3) 4 (0.9)
Vomiting 6 (8.6) 6 (8.3) 9 (2.0) 10 (2.3)
Nausea 5 (7.1) 6 (8.3) 7 (1.6) 13 (3.0)
Infection 3 (4.3) 0 3 (0.7) 0
Diarrhoea 2 (2.9) 0 2 (0.5) 0
Sensory neuropathy 2 (2.9) 0 2 (0.5) 0
Fever 1 (1.4) 0 1 (0.2) 0
Nail toxicity 1 (1.4) 0 1 (0.2) 0
Skin toxicity 1 (1.4) 0 1 (0.2) 0
Cardiotoxicity 1 (1.4) 0 1 (0.2) 0
Haemorrhage 1 (1.4) 0 1 (0.2) 0
Abdominal pain 1 (1.4) 0 1 (0.2) 0
Pneumopathy 1 (1.4) 0 1 (0.2) 0
Stomatitis 0 3 (4.2) 0 3 (0.7)
ET¼epirubicin plus docetaxel; FEC¼5-fluorouracil plus epirubicin plus cyclo-
phosphamide.
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lparticularly in terms of the ORR and median TTP relative to the
established anthracycline-based triple combination of FEC (with
the same epirubicin dose of 75mgm
 2). The ORR in the ET group
was almost twice that of FEC (63.1 vs 34.3%), with two CR after ET
treatment (compared with one CR with FEC). It should be noted
that the tumour response rate with FEC in this study was
somewhat lower than that reported in some other trials (Del
Mastro et al, 2001; Baldini et al, 2003), but the population included
in these trials presented a locally advanced breast cancer, although
these response rates (41%) were consistent with those reported in a
recent phase III study (Capotorto et al, 2003) of the same FEC
regimen.
The median TTP was 7.8 months (95% CI, 5.8–9.6 months) for
ET and 5.9 months (95% CI, 4.6–7.8 months) for FEC. The median
survival was 34 months for ET and 28 months for FEC, although
the survival curves appeared similar. However, this outcome may
have been affected by the unplanned use of second-line (during the
poststudy period); 56.9% of FEC-treated patients received subse-
quently docetaxel, whereas only 8.6% of ET-treated patients.
A prospectively designed and appropriately powered compara-
tive trial, lacking potentially confounding late interventions, would
be needed to investigate potential differences in survival.
Our results are consistent with other studies in which docetaxel
has been combined with an anthracycline. Overall response rates
of 57–79% were reported with 3-weekly combinations of docetaxel
60–80mgm
 2 in five first-line noncomparative studies in a total
of 170 patients with metastatic breast cancer (Sparano et al, 2000;
Baltali et al, 2001; Lippe et al, 2002; Aihara et al, 2003; Morales et al,
2004). Previous noncomparative studies of 3-weekly epirubicin
75mgm
 2 plus docetaxel 75mgm
 2 have yielded overall tumour
response rates of 67–84%, with overall survival of up to
approximately 2 years (Airoldi et al, 2001; Yeo et al, 2002; Morales
et al, 2004).
Adverse events in the present study were predictable. Reversible
myelosuppression was the dose-limiting toxicity in both treatment
arms, although this was more common with ET than with FEC.
Nevertheless, fewer than 5% of cycles in the ET group required
dose adjustment (of epirubicin) or G-CSF support. Toxicity was
higher overall with ET than with FEC, but frequencies and
severities of adverse events were acceptable in the context of the
disease being treated and the high response rate with ET, and were
manageable in both groups. Alopecia and asthenia were the most
common nonhaematologic toxicities. Neurosensory symptoms and
cardiotoxicity were very infrequent; the incidence of sensory
neuropathy reported (2.9%) can be compared to the incidence of
around 4–5% with docetaxel 100mgm
 2 as monotherapy
according to collated data from patients with metastatic breast
cancer (Aventis Pharmaceuticals Inc., 2003).
Previous phase II studies have shown similar profiles and
frequencies of adverse events when docetaxel is combined with an
anthracycline. Haematologic adverse events (most notably neu-
tropenia) were most common, with no excessive cardiac toxicity or
any indication that the addition of docetaxel to doxorubicin
increases the cardiotoxicity of the latter (Sparano et al, 2000;
Baltali et al, 2001; Lippe et al, 2002; Aihara et al, 2003; Morales et al,
2004). In one phase II noncomparative trial of epirubicin and
docetaxel, no grade 4 nonhaematologic adverse events and very
low levels of cardiotoxicity (reversible congestive heart failure in
one of 60 patients only) were observed (Yeo et al, 2002), whereas in
another study there was no grade 3–4 cardiac toxicity and no
treatment-related mortality among 46 patients (Airoldi et al, 2001).
A further recent trial of 133 patients reported that two withdrew
treatment due to cardiotoxicity, although none developed con-
gestive heart failure (Morales et al, 2002).
The results of this study are also consistent with final data from
a recent phase III comparison of docetaxel 75mgm
 2 plus
doxorubicin 50mgm
 2 (AT) vs doxorubicin 60mgm
 2 plus
cyclophosphamide 600mgm
 2 (AC) in 429 patients with meta-
static breast cancer in which the ORR was significantly higher with
the former regimen (59 vs 47%; P¼0.009) and the median TTP
was superior for AT (37.3 vs 31.9 weeks with AC; P¼0.014). The
median survival in this study was similar at approximately 22
months in both arms (Nabholtz et al, 2003). Grade 3 and 4
neutropenia was frequent in both groups, although febrile
neutropenia (33 vs 10%; Po0.001) and infection (8 vs 2%;
P¼0.01) were more common in patients receiving AT. These
findings are consistent with those in the present study.
Of particular interest are the results of the large phase III first-
line comparison of epirubicin 75mgm
 2 plus paclitaxel
200mgm
 2 vs epirubicin 75mgm
 2 plus cyclophosphamide
600mgm
 2 carried out by the UKCCCR in 705 patients
(Carmichael, 2001). The ORR was 67% in the epirubicin plus
paclitaxel arm and 57% with epirubicin plus cyclophosphamide.
Interestingly, there was no significant difference between treat-
ments in the median progression-free (6.5 vs 6.7 months; primary
end point) and overall (13.7 vs 13.8 months) survival after a
median follow-up of 15 months. Of the 705 patients, 70% received
all six planned cycles, with equivalent epirubicin dose intensity in
both arms. Dose reductions and delays were attributable chiefly to
myelosuppression and infection, and 46 and 37%, respectively, of
patients receiving epirubicin plus paclitaxel and epirubicin plus
cyclophosphamide experienced grade 3–4 toxicity (excluding
alopecia). Severe mucositis (6 vs 2%; P¼0.02) and neurotoxicity
(5 vs 1%; P¼0.003) were more common in patients receiving
epirubicin plus paclitaxel than in those receiving epirubicin plus
cyclophosphamide. These findings may be compared with those of
the present study, which showed grade 3–4 sensory neuropathy in
2.9% of patients receiving ET, with no grade 3–4 stomatitis. In the
UKCCCR study, severe infection was observed in 14% patients
receiving epirubicin plus paclitaxel and 11% of patients on
epirubicin plus cyclophosphamide, which may be compared with
an incidence of grade 3–4 infection of only 4.3% in ET patients in
the present trial. Overall, therefore, contrast of the UKCCCR data
with the results of the present study suggests a potential advantage
of docetaxel over paclitaxel when either is combined with
epirubicin for metastatic breast cancer, although comparative
trials will be required to confirm this (Jones et al, 2003).
In summary, the combination of docetaxel plus epirubicin is a
highly active first-line treatment for metastatic breast cancer with
acceptable toxicity, particularly for patients with symptomatic
nonindolent disease. Evaluation of this combination is already
underway in the adjuvant setting.
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